1562results about "Amide active ingredients" patented technology

The present disclosure provides methods of treating opioid use disorder in a patient in need thereof by intravenously administering to the patient a therapeutically effective amount of ibogaine or pharmaceutically acceptable salt thereof.

The invention relates to the technical field of pharmaceutical preparations, and discloses a composition with liver protection and antioxidation effects and a preparation method thereof.The composition is prepared from galactosamine modified astragalus membranaceus exosome, schisandra chinensis nanocrystals, liquorice-chitosan nanoparticles, lactobacillus acidophilus freeze-dried powder, beta-(1, 3) / (1, 3, 4-tetramethyl-1, 3-pentanediol monoisobutyrate) sourced from saccharomyces cerevisiae, and beta-(1, 3, 4-tetramethyl-1, 3-pentanediol monoisobutyrate). And (6) a dextran, grape exosome-curcumin hybrid vesicle freeze-dried powder, a curcumin-mitochondrial targeting peptide compound, a resveratrol-hydroxypropyl-beta-cyclodextrin inclusion compound and reduced panthenol. According to the liver-protecting and anti-oxidation composition disclosed by the invention, multi-dimensional intervention on liver protection is realized through an elaborately designed ternary system. The system is composed of a traditional Chinese medicine extract, a microorganism-plant exosome combination and a high-bioavailability antioxidant, all the parts have a synergistic effect, and the liver protection effect is remarkably improved.

The present invention relates to the use of N-palmitoylethanolamide (known as palmitoylethanolamide or PEA) in combination with a non-steroidal anti-inflammatory drug in the treatment of inflammatory pain. In particular, the present invention is directed to palmitoylethanolamide for use in the treatment of inflammatory pain, in particular non-neuropathic inflammatory pain, where palmitoylethanolamide is administered as needed in association or combination with a non-steroidal anti-inflammatory drug, where said administration is separate, combined, or simultaneous.

The present invention relates to a use of THBS1 as a novel combination drug target that can overcome drug resistance of a targeted anticancer agent. A THBS1 inhibitor according to the present invention inhibits the drug resistance of a target anticancer agent and thus increases an anticancer effect when administered in combination with a target anticancer agent. Accordingly, the present invention can overcome resistance to a targeted anticancer agent and increase a treatment success rate of anticancer drugs for cancer patients, thereby suggesting new possibilities for treatment strategies using targeted anticancer drugs and contributing to the realization of precision medicine.

Provided herein are compositions and methods for treating patients with Usher syndrome associated retinitis pigmentosa (UARP) comprising identifying that the subject has UARP and administering to the animal or human an effective amount of an N-acetylcysteine amide (NACA) sufficient to protect vision and inhibit degradation of Ellipsoid Zone (EZ) area and retinal sensitivity. In one example, the NACA formulation is doses at 50, 100, 200, 201, 210, 225, 250, 275, 300, 350, 400, 450, 500, 600, 700, 750, 800, 900, or 1,000 mg / day.

The present invention provides compounds useful in the treatment of conditions associated with aberrant activity of voltage gated sodium channel NaV1.8, and methods of using these compounds to treat conditions such as pain, pruritus, and cough in subjects.

The invention provides an external application medicine for incontinent dermatitis and a preparation method thereof. The composition is prepared from active ingredients such as a radix sophorae flavescentis extract, calamine, vitamin E, ceramide, a herba portulacae extract, glycyrrhizic acid, chitosan and colloidal oat powder according to a specific proportion. Moisturizing matrixes such as sodium hyaluronate and glycerol and functional components such as tea tree essential oil are supplemented. And through a preparation process of matching high-speed shearing with ultrasonic dispersion, uniform dispersion and stability of each component are ensured. Experimental results show that the composition shows a remarkable synergistic effect in the aspects of anti-inflammation, antibiosis, skin barrier repair and the like, the comprehensive relieving and repairing effect of the composition is superior to that of a conventional drug control, and all the components and a special preparation process are necessary for achieving the optimal effect. The product has no irritation to human skin, is good in safety, can be prepared into various dosage forms such as cream, hydrogel or spray, and is suitable for nursing and repairing sensitive skin.

Methods and compositions comprising one or more dopamine neuronal activity enhancers (e.g., dopamine receptor agonists), pantethine and solubilized curcumin for use in treating NAFLD and NASH are provided.Methods and compositions comprising one or more dopamine neuronal activity enhancers (e.g., dopamine receptor agonists), pantethine and solubilized curcumin for use in treating NAFLD and NASH are provided.

The invention relates to the technical field of fullerene derivatives, in particular to a structure-determined fullerene derivative, a structure-determined water-soluble fullerene derivative and preparation methods and applications of the structure-determined fullerene derivative and the structure-determined water-soluble fullerene derivative. The invention provides a fullerene derivative with a determined structure. The structural formula of the fullerene derivative is shown as (VII). The invention also provides a method for preparing the fullerene derivative with the determined structure shown as (VII). The water-soluble fullerene derivative determined by the structure as shown in (VII) provided by the invention has good water solubility and oxidation resistance.

Disclosed are effective, non-irritating, skincare formulations containing an alpha hydroxy acid and urea or a urea derivative for topical application to the skin. The disclosed topical formulations provide enhanced penetration of the active ingredients to the skin for the treatment of amenable skin conditions, such as very dry skin and keratosis pilaris, as well as for improvement of aesthetic skin properties. Also provided are methods for therapeutic treatment of dermatological conditions by topically applying a formulation comprising (% w / w) at least 10% alpha hydroxy acid and at least 10% urea. The formulations may be cream emulsions, spray-ons, among other delivery systems.

The present invention provides an SLC6A19 inhibitor compound, a pharmaceutical composition, a preparation method, and a use. The compound has a good SLC6A19 inhibitory effect, and is used for the treatment of SLC6A19-mediated disorders and / or diseases, such as phenylketonuria, and the preparation of drugs for such disorders or diseases.

The invention belongs to the technical field of plant care essential oil extraction, and particularly relates to sanshool delayed care essential oil and a preparation method thereof. The invention discloses a sanshool-enriched lipid composition which is prepared from the following components in parts by weight: 0.05 to 0.1 part of sanshool-enriched fraction, 1 to 2 parts of solid lipid, 1 to 1.5 parts of liquid lipid, 1.5 to 2.5 parts of stable surfactant, 1 to 2 parts of cosurfactant, 3 to 5 parts of glycerol, 0.2 to 0.5 part of soothing anti-irritation component, 0.05 to 0.1 part of sodium hyaluronate, 0.1 to 0.3 part of hydroxypropyl methyl cellulose, 0.05 to 0.1 part of antioxidant and the balance of purified water. According to the invention, sanshool is used as a core functional factor, and through collaborative design of supercritical extraction, molecular distillation purification, NLC carrier encapsulation and a soothing film-forming system, contradictions of effectiveness, mildness and the like in an existing scheme are solved, and mild desensitization, stable controlled release, reduction of stimulation and migration risks and improvement of tolerance and action consistency are realized.

The present disclosure provides a method of treating estrogen receptor-positive (ER+) breast cancer, comprising the combined administration of therapeutically effective amounts of a KAT6A / B inhibitor and a Menin inhibitor to a patient in need thereof.

The present invention relates to an improved kit for preparing injectable carmustine solutions, methods of preparing and administering such solutions, and methods of treatment with such solutions. The kit includes a product vial containing lyophilised carmustine and a diluent vial containing an ethanol-free non-aqueous diluent. Reconstitution of the lyophilised carmustine in the ethanol-free non-aqueous diluent results in a carmustine solution with improved solubility and stability.

A method for treating liver cancer, in particular in subjects exhibiting homologous recombination deficiency (HRD) positive, comprises the use of hydroxyurea methyl acyl fulvene. The compounds may be administered as monotherapy or in combination with other chemotherapeutic agents and / or radiation therapy.

The invention discloses a preparation method and application of a water-soluble plant extract for cosmetics, and belongs to the technical field of biology. The preparation method comprises the following steps: mixing glycyrrhizic acid and a hydrophobic plant extract according to a molar mass ratio of (10-12): 1, adding 5-7 times by mass of absolute ethyl alcohol, heating and stirring, and concentrating under reduced pressure until concentrated feed liquid is in a semi-solid state; adding 5-10 times by mass of nicotinamide into the concentrated feed liquid, supplementing 10-20 times by mass of water, heating and stirring again, filtering under reduced pressure, drying and crushing to obtain the water-soluble plant extract. Experiments prove that the coating rate of the glycyrrhizic acid and the hydrophobic plant extract can be greatly increased by changing the solvent in which the hydrophobic plant extract reacts with the glycyrrhizic acid, and meanwhile, the assembled molecules can be sealed by adding nicotinamide later, so that the stability of the assembled molecules in normal-temperature water is greatly improved, and the subsequent application risk of the assembled molecules is reduced.

The present specification relates to a compound as a UBR box domain ligand. The present specification provides a small molecule compound that binds to the UBR box domain. Further, the present specification provides a composition for inhibiting UBR box domain substrate binding, including a ligand compound that binds to a UBR box domain, a pharmaceutical composition for treating UBR-related disease, and a use thereof.

The invention relates to oral analgesic compositions for alleviation of perceived nicotine irritation through inhibition or blocking of nicotine activated receptors or ion channels in the gastrointestinal tract, including the oral cavity. The composition of the invention comprises one or more nicotine sources, one or more buffering agents,5 and at least two antagonists in an effective amount to inhibit or block nicotine agonist activation of Nicotinic Acetylcholine Receptors (nAChR) and / or Transient Receptor Potential (TRP) ion channels, the at least two antagonists being selected from the group consisting of a first antagonist comprising camphor or one or more compounds resembling camphor, a second antagonist comprising eucalyptol, and a 10 third antagonist comprising (1R,2S,5R)-N-(4-Methoxyphenyl)-5-methyl-2-(1- methylethyl)cyclohexanecarboxamide (WS-12).

To provide an excellent pest control agent 【Solution means】General formula [I] 【Chemical formula 1】 JPEG2026077605000071.jpg4066[wherein, R 1 , R 4 each independently represents a substituent such as an alkyl group, R 2 , R 3 , R 5 each independently represents a hydrogen atom or a substituent such as an alkyl group, and R 6 represents a hydrogen atom or a halogen atom.]. Provided are N-benzylamide compounds represented by the formula or salts thereof, and pest control agents containing them as active ingredients.

The present disclosure describes methods of specifically modulating the activity and / or number of regulatory T (Treg) cells within a tumor in a subject. Such methods may be used to reduce the number of regulatory T cells within a tumor in a subject, as well as to inhibit tumor growth in a subject with cancer without eliciting an autoimmune response. This method relies on the inhibition of CD36 or PPARbeta.

The present invention relates to a pharmaceutical liquid composition, wherein said liquid composition comprises at least one cooling agent comprising of a phenyl ring containing a polar side group at least one viscosity enhancing agent and at least one surfactant. The invention also relates to a method to produce such a pharmaceutical composition as well as a method of alleviating a symptom selected from the group consisting of cough, nasal congestion and sore throat in a subject comprising administering the composition according to any of preceding claims.

The present application provides compositions comprising an endoplasmic reticulum / sarcoplasmic reticulum calcium channel inhibitor and a gap junction inhibitor for use in various methods, such as methods for treating or preventing necrosis, cell death, tissue damage, or organ damage. The compositions may also comprise a cell membrane calcium channel inhibitor and / or a calcium chelator. Also provided are compositions comprising a calpain inhibitor and a cathepsin inhibitor for use in various methods. Furthermore, compositions comprising a calcium chelator, preferably at a relatively high dose, for use in various methods are provided.

The present invention relates to new inhibitors of the transcription factor FOXA1 and / or FOXA2 for use in a method of treatment of cancer or other FOXA1 / FOXA2-dependent diseases.

The present disclosure provides compounds of Formula (I), their pharmaceutically acceptable salts, and pharmaceutical compositions thereof, which relate to novel DNA polymerase γ (POLγ) modulators.

In certain embodiments, Formula I: 【Chemical 1】 Compounds of JPEG2025520456000046.jpg5339 or pharmaceutically acceptable salts or solvates thereof, compositions comprising a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, and their use in the treatment of certain diseases or disorders (e.g., cancer, fibrosis, chronic inflammation) etc. are provided herein.

Provided are compositions that include a histone deacetylase inhibitor (HDACi) encapsulated in and / or otherwise associated with a nanoparticle. In some embodiments, the HDACi is romidepsin, vorinostat, belinostat, panobinostat, and / or chidamide. In some embodiments, the nanoparticle is a poly(D,L-lactide)-PEG-methyl ether (mPEG-PDLLA) nanopolymer. Also provided are methods for treating diseases, disorders, and / or conditions associated with sensitivity to histone deacetylase inhibitors, such as but not limited to tumors and / or cancers; and methods for inhibiting the growth, proliferation, and / or metastasis of a tumor and / or a cancer associated with sensitivity to histone deacetylase inhibitors by administering an effective amount of a composition as disclosed herein, which methods can optionally include administering at least one additional therapeutically active agent, such as but not limited to a chemotherapeutic agent.

The present invention relates to sulforaphane glycoconjugate compounds, as well as to the synthesis and therapeutic uses thereof for treating inflammatory diseases.